Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers.
Aftercare
/ methods
Antigens, CD19
/ immunology
Antigens, Neoplasm
/ immunology
Blood Donors
/ legislation & jurisprudence
Cell Transplantation
/ adverse effects
Health Personnel
/ education
Humans
Immunotherapy, Adoptive
/ adverse effects
Neoplasms
/ therapy
Patient Selection
Receptors, Chimeric Antigen
/ immunology
T-Lymphocytes
/ immunology
Transplants
Tumor Microenvironment
/ immunology
ATMP
CAR-T Specialist
CAR-T Unit
CAR-T cells
CAR-T process
GMP
JACIE
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
05
2020
accepted:
06
10
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
4
5
2021
Statut:
epublish
Résumé
Chimeric Antigen Receptor-T cells (CAR-T) are considered novel biological agents, designed to selectively attack cancer cells expressing specific antigens, with demonstrated clinical activity in patients affected with relapsed/refractory B-cell malignancies. In consideration of their complexity, the use of CAR-T requires dedicated clinical setting and health care practitioners with expertise in the selection, treatment, and management of toxicities and side effects. Such issue appears particularly important when contextualized in the rapid progress of CAR-T cell treatment, translating into a constant need of updating and evolution. Moreover, the clinical grade manufacturing of CAR-T cells is complex and implies articulated regulatory and organizational aspects. The main goal of this review is to summarize and provide an accurate analysis of the clinical, logistic, and regulatory requirements of CAR-T cell centers. Finally, we describe a new occupational figure called "CAR-T specialist" devoted to the establishment and coordination of the required facilities and regulatory landscape in the context of cancer centers.
Identifiants
pubmed: 33193333
doi: 10.3389/fimmu.2020.565236
pmc: PMC7662555
doi:
Substances chimiques
Antigens, CD19
0
Antigens, Neoplasm
0
CD19 molecule, human
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
565236Informations de copyright
Copyright © 2020 Gotti, Defrancesco, D’Angelo, Basso, Crotto, Marinelli, Maccalli and Iaconianni.
Références
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Nat Rev Clin Oncol. 2019 Jan;16(1):45-63
pubmed: 30082906
Sci Transl Med. 2016 Sep 7;8(355):355ra116
pubmed: 27605551
J Clin Oncol. 2015 Feb 20;33(6):540-9
pubmed: 25154820
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85
pubmed: 30576834
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Lab Invest. 1996 Jan;74(1):43-7
pubmed: 8569196
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Mol Ther. 2016 Jun;24(6):1135-1149
pubmed: 27019998
J Clin Invest. 2016 Oct 3;126(10):3814-3826
pubmed: 27571406
Mol Ther. 2017 May 3;25(5):1248-1258
pubmed: 28366766
Prog Exp Tumor Res. 1970;13:1-27
pubmed: 4921480
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Mol Ther Nucleic Acids. 2013 Jul 09;2:e105
pubmed: 23839099
Cells. 2018 Oct 01;7(10):
pubmed: 30275435
Adv Immunol. 2016;130:279-94
pubmed: 26923004
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
Mol Ther. 2017 Jan 4;25(1):285-295
pubmed: 28129122
Oncoimmunology. 2014 Jan 1;3(1):e27456
pubmed: 24800163
Semin Immunopathol. 2011 Jul;33(4):335-40
pubmed: 21461991
Trends Immunol. 2005 Feb;26(2):111-7
pubmed: 15668127
Mol Ther. 2011 Mar;19(3):432-8
pubmed: 21358705
Transplant Rev. 1971;7:3-25
pubmed: 5146537
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Nat Biotechnol. 2002 Jan;20(1):70-5
pubmed: 11753365
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
Curr Opin Immunol. 2013 Apr;25(2):261-7
pubmed: 23579076
Am Soc Clin Oncol Educ Book. 2018 May 23;38:830-837
pubmed: 30231350
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Blood. 2015 Jun 25;125(26):4017-23
pubmed: 25999455
Biol Blood Marrow Transplant. 2019 Apr;25(4):e123-e127
pubmed: 30586620
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
J Hematol Oncol. 2017 Mar 29;10(1):78
pubmed: 28356156
Curr Top Microbiol Immunol. 2011;344:149-72
pubmed: 20700700
Oncoimmunology. 2018 Feb 15;7(5):e1423167
pubmed: 29721373
Immunity. 2016 Mar 15;44(3):698-711
pubmed: 26982367
Oncoimmunology. 2018 Mar 15;7(6):e1433518
pubmed: 29872565
BMJ Open. 2017 Nov 12;7(11):e017075
pubmed: 29133316
Gene Ther. 2020 Feb;27(1-2):85-95
pubmed: 31919448
J Clin Invest. 2007 May;117(5):1204-12
pubmed: 17476350
Med Oncol. 2018 Apr 12;35(5):70
pubmed: 29651744
Blood. 2012 Mar 22;119(12):2709-20
pubmed: 22160384
Cancer Res. 2011 Feb 15;71(4):1263-71
pubmed: 21303976
Curr Top Microbiol Immunol. 2011;344:1-24
pubmed: 20512556
Int J Mol Sci. 2019 Nov 26;20(23):
pubmed: 31779130
Front Immunol. 2018 Oct 26;9:2486
pubmed: 30416506
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Immunol Res. 2003;27(2-3):341-56
pubmed: 12857980
Curr Res Transl Med. 2017 Sep;65(3):93-102
pubmed: 28988742
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Immunol Rev. 2014 Jan;257(1):83-90
pubmed: 24329791
Pharmacol Ther. 2020 Jan;205:107419
pubmed: 31629009
Sci China Life Sci. 2016 Apr;59(4):386-97
pubmed: 26961900
J Clin Immunol. 2012 Oct;32(5):1059-70
pubmed: 22526592
J Clin Oncol. 2017 Jun 1;35(16):1803-1813
pubmed: 28291388
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Cancer Cell. 2019 Nov 11;36(5):471-482
pubmed: 31715131
Cancer Immunol Res. 2014 Feb;2(2):112-20
pubmed: 24579088
Med Oncol. 2018 May 5;35(6):87
pubmed: 29730801
Haematologica. 2020 Jan 31;105(2):297-316
pubmed: 31753925
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369
Ann Oncol. 2018 Jan 1;29(1):84-91
pubmed: 29228097
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35
pubmed: 17855649
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358